AR107042A1 - Inhibidores de la tirosina quinasa de bruton y métodos de su uso - Google Patents

Inhibidores de la tirosina quinasa de bruton y métodos de su uso

Info

Publication number
AR107042A1
AR107042A1 ARP160103789A ARP160103789A AR107042A1 AR 107042 A1 AR107042 A1 AR 107042A1 AR P160103789 A ARP160103789 A AR P160103789A AR P160103789 A ARP160103789 A AR P160103789A AR 107042 A1 AR107042 A1 AR 107042A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
haloalkyl
phenyl
optionally substituted
Prior art date
Application number
ARP160103789A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR107042A1 publication Critical patent/AR107042A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP160103789A 2015-12-10 2016-12-12 Inhibidores de la tirosina quinasa de bruton y métodos de su uso AR107042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
AR107042A1 true AR107042A1 (es) 2018-03-14

Family

ID=57681784

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103789A AR107042A1 (es) 2015-12-10 2016-12-12 Inhibidores de la tirosina quinasa de bruton y métodos de su uso

Country Status (30)

Country Link
US (5) US10717745B2 (https=)
EP (2) EP3386991B1 (https=)
JP (2) JP6835846B2 (https=)
KR (1) KR102103395B1 (https=)
CN (2) CN108884106A (https=)
AR (1) AR107042A1 (https=)
AU (1) AU2016366541B2 (https=)
BR (1) BR112018011526B1 (https=)
CA (1) CA3007990C (https=)
CY (1) CY1123263T1 (https=)
DK (1) DK3386991T3 (https=)
EA (1) EA035168B1 (https=)
ES (1) ES2805835T3 (https=)
HR (1) HRP20201193T1 (https=)
HU (1) HUE049502T2 (https=)
IL (1) IL259863B (https=)
JO (1) JO3794B1 (https=)
LT (1) LT3386991T (https=)
MA (2) MA53110A (https=)
MD (1) MD3386991T2 (https=)
ME (1) ME03803B (https=)
MX (1) MX387590B (https=)
PL (1) PL3386991T3 (https=)
PT (1) PT3386991T (https=)
RS (1) RS60604B1 (https=)
SI (1) SI3386991T1 (https=)
SM (1) SMT202000404T1 (https=)
TW (1) TWI729047B (https=)
UY (1) UY37015A (https=)
WO (1) WO2017100662A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
US20200079790A1 (en) * 2017-03-15 2020-03-12 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES2949871T3 (es) 2019-04-11 2023-10-03 Janssen Pharmaceutica Nv Anillos de piridina que contienen derivados como inhibidores de MALT1
US20230094146A1 (en) * 2020-01-07 2023-03-30 Medshine Discovery Inc. Deuterated thienopyridine compound
EP4301365A1 (en) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
AU2022284369A1 (en) 2021-06-04 2024-01-25 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
JP2024526241A (ja) 2021-06-30 2024-07-17 ヤンセン ファーマシューティカ エヌ.ベー. ブルトン型チロシンキナーゼの阻害剤及びその使用方法
KR20240046170A (ko) 2021-08-09 2024-04-08 얀센 파마슈티카 엔브이 B-세포 악성종양의 치료에 사용하기 위한 조성물
AU2023221549A1 (en) * 2022-02-18 2024-10-03 Janssen Pharmaceutica Nv Synthesis of bruton's tyrosine kinase inhibitors
WO2025262118A1 (en) 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
AU2006278627B2 (en) 2005-08-08 2011-08-18 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
US7427625B2 (en) * 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
EP2471789B9 (en) * 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
US20140249105A1 (en) 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
EA201591685A1 (ru) 2013-03-15 2016-01-29 Янссен Фармацевтика Нв Способы и промежуточные соединения для получения лекарственного препарата
EP3080103B9 (en) * 2013-12-11 2018-09-19 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
MD3386991T2 (ro) 2020-11-30
CN108884106A (zh) 2018-11-23
IL259863A (en) 2018-07-31
AU2016366541A1 (en) 2018-05-31
US11319329B2 (en) 2022-05-03
MA43409B1 (fr) 2020-10-28
AU2016366541B2 (en) 2021-05-13
US20230097422A1 (en) 2023-03-30
US20170283430A1 (en) 2017-10-05
JP6835846B2 (ja) 2021-02-24
KR20180093974A (ko) 2018-08-22
ME03803B (me) 2021-04-20
BR112018011526B1 (pt) 2024-02-27
RS60604B1 (sr) 2020-08-31
EA201891378A1 (ru) 2018-12-28
EP3719022A1 (en) 2020-10-07
US20190276471A1 (en) 2019-09-12
EP3386991B1 (en) 2020-06-03
PT3386991T (pt) 2020-08-18
US12065446B2 (en) 2024-08-20
BR112018011526A2 (pt) 2018-11-21
JP2018536686A (ja) 2018-12-13
ES2805835T3 (es) 2021-02-15
TWI729047B (zh) 2021-06-01
HUE049502T2 (hu) 2020-09-28
UY37015A (es) 2017-06-30
JP2021073286A (ja) 2021-05-13
NZ742484A (en) 2021-09-24
US20210101910A1 (en) 2021-04-08
US10717745B2 (en) 2020-07-21
LT3386991T (lt) 2020-08-25
CN113121562B (zh) 2022-09-13
SMT202000404T1 (it) 2020-09-10
MX387590B (es) 2025-03-18
JP7072690B2 (ja) 2022-05-20
HRP20201193T1 (hr) 2020-11-13
CA3007990C (en) 2024-01-02
EP3386991A1 (en) 2018-10-17
KR102103395B1 (ko) 2020-04-23
JO3794B1 (ar) 2021-01-31
WO2017100662A1 (en) 2017-06-15
CA3007990A1 (en) 2017-06-15
IL259863B (en) 2020-06-30
CN113121562A (zh) 2021-07-16
CY1123263T1 (el) 2021-12-31
PL3386991T3 (pl) 2021-03-08
US20240383914A1 (en) 2024-11-21
TW201734021A (zh) 2017-10-01
DK3386991T3 (da) 2020-07-13
MA53110A (fr) 2021-05-12
EA035168B1 (ru) 2020-05-08
MX2018007075A (es) 2018-11-09
US10934310B2 (en) 2021-03-02
SI3386991T1 (sl) 2020-08-31

Similar Documents

Publication Publication Date Title
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR109805A1 (es) Derivados de oxadiazol microbiocidas
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR101174A1 (es) Imidazopirazinas como inhibidores de lsd1
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR110405A1 (es) Compuestos
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR106099A1 (es) Compuestos bicíclicos como inhibidores duales de atx / ca
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR107041A1 (es) Inhibidores de la tirosina kinasa de bruton y métodos de su uso
AR106100A1 (es) Compuestos bicíclicos como inhibidores duales atx / ca
AR087870A1 (es) Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina
AR093504A1 (es) 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR102825A1 (es) Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre
AR100713A1 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor

Legal Events

Date Code Title Description
FG Grant, registration